Active, not recruitingPhase 2NCT06106295
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Studying NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Irina Bancos, MDMayo Clinic
- Intervention
- Metyrapone(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- Mayo Clinic Minnesota, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06106295 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07361874IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionUniversity of Texas Southwestern Medical Center
- RECRUITINGPHASE4NCT07247058Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)Johns Hopkins University
- RECRUITINGPHASE2NCT07104812Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
See all trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor →